On Mar. 24, 2015, the U.S. Food and Drug Administration (FDA) licensed an additional combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine (DTaP-IPV) (Quadracel, Sanofi Pasteur). Quadracel is the second DTaP-IPV vaccine to be licensed for use among children aged 4 through 6 years in the United States.

Quadracel is approved for administration as a fifth dose in the DTaP series and as a fourth or fifth dose in the IPV series in children aged 4 through 6 years who have received 4 doses of DTaP-IPV-Hib (Pentacel, Sanofi Pasteur) and/or DTaP (Daptacel, Sanofi Pasteur) vaccine. This report summarizes the indications for Quadracel vaccine and provides guidance from the Advisory Committee on Immunization Practices (ACIP) for its use.

The ACIP Combination Vaccines Work Group, including liaison representatives from the American Academy of Pediatrics, the American Academy of Family Physicians, the National Association of Pediatric Nurse Practitioners, and the American Academy of Physician Assistants, reviewed data on the safety and immunogenicity of Quadracel vaccine. On the basis of the clinical data reviewed, expert opinion of the work group, and feedback from ACIP liaison organizations, ACIP endorsed the licensed indications for this vaccine. Both licensed DTaP-IPV vaccine formulations are included in the federal Vaccines for Children Program